March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Pigment Epithelium Derived Factor (PEDF) Inhibits Activation of Stat3, an Important Transcription Factor in Metastatic Ocular Melanoma
Author Affiliations & Notes
  • John Lattier
    Ophthalmology, Emory University, Atlanta, Georgia
  • Chaunte Stampley
    Ophthalmology, Georgia Health Sciences University, Augusta, Georgia
  • Hua Yang
    Ophthalmology, Emory University, Atlanta, Georgia
  • Manuela Bartoli
    Ophthalmology, Georgia Health Sciences University, Augusta, Georgia
  • Hans Grossniklaus
    Ophthalmology, Emory University, Atlanta, Georgia
  • Footnotes
    Commercial Relationships  John Lattier, None; Chaunte Stampley, None; Hua Yang, None; Manuela Bartoli, None; Hans Grossniklaus, None
  • Footnotes
    Support  NIH EY007092
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5308. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      John Lattier, Chaunte Stampley, Hua Yang, Manuela Bartoli, Hans Grossniklaus; Pigment Epithelium Derived Factor (PEDF) Inhibits Activation of Stat3, an Important Transcription Factor in Metastatic Ocular Melanoma. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5308.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the effects of pigment epithelium derived factor (PEDF) on Stat3 activation. Stat3 is a pro-metastatic transcription factor that requires phosphorylation at Tyr-705 in order to dimerize, translocate to the nucleus, and bind DNA. In cases of metastatic uveal melanoma, the most common form of eye cancer in adults, the liver is the predominant site of metastasis. PEDF is a secreted protein in the liver that inversely correlates with metastatic tumor growth as shown in PEDF-/- C57BL/6 mice. We hypothesize that PEDF has an inhibitory effect on Stat3 phosphorylation thus preventing metastatic melanoma growth.

Methods: : Using bovine retinal endothelial cells (BREC) in serum-free media, an established cell line for studying Stat3, phosphorylation of Stat3 at Tyr-705 was induced by one hour in hypoxic conditions at 1% O2. Control cells were grown at 20% O2. Cells were treated with 50ng/mL PEDF, either for 30minutes prior to hypoxia or at the midpoint of 1 hour in hypoxia. Separately, Stat3 was activated by 20ng/mL VEGF for 30 minutes versus non-treated control cells. To test the effect of PEDF on VEGF-mediated Stat3 phosphorylation, cells were pre-treated with 50ng/mL PEDF for 5 minutes before VEGF treatment. Additionally, cells were treated with 50ng/mL PEDF alone for either 5, 15, 30, or 60 minutes. Protein was collected, and western blots were performed.

Results: : Hypoxia and VEGF treatment both upregulated Stat3 phosphorylation versus control. PEDF treatment, both before and during hypoxia, and before VEGF treatment, returned phospho-Stat3 to control levels. PEDF alone, however, upregulated Stat3 phosphorylation versus control.

Conclusions: : PEDF has an inhibitory effect on Stat3 activation in both hypoxic and VEGF-rich culture conditions. Conversely, PEDF alone promotes Stat3 activation. Thus, PEDF treatment may not have an anti-metastatic effect unless the system is hypoxic or if VEGF is already present.

Keywords: phosphorylation • melanoma • growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×